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Incorporating Treatment into Life: A Retrospective
Analysis of Clinical, Financial and Quality of Life
Measures Following Hematopoietic Stem Cell Transplant
in Patients Receiving Home Subcutaneous Immune
Globulin
Kelly O'Donnell Bertolazzi 1, Gretchen Ayer 2,
Linda Abramovitz 3. 1 Crescent Healthcare, a Walgreen's
Infusion Company; 2 Crescent Healthcare, a Walgreens Infusion
Company; 3 University of California, San Francisco
Hematopoietic stem cell transplant, (HSCT) is a treatment
option for children with severe combined immune deﬁ-
ciency (SCID). Long term use of gamma globulin is some-
times necessary for patients who do not have complete
B-cell recovery. Recently, the use of subcutaneous immune
globulin (SCIG) has become an increasingly popular alter-
native to IVIG. The purpose of this poster is to report on
a quality assurance project which evaluated the clinical
management and experiences of 11 patients with SCID who
transitioned from hospital outpatient IVIG infusions to SCIG
administration at home.
The home infusion pharmacy and nursing evaluations of
11 post BMT patients, (ages 1-25, median age 4) were
reviewed. The patients received a total of 958 SCIG infusions
for an average of 87 infusions per patient. The clinical
management model for these home SCIG patients included
initial SCIG training from a home infusion RN. In addition,
ongoing pharmacist monitoring and management included:
identiﬁcation and management of SCIG related side effects,
weight, dose, compliance, reported infections, antibiotic use
and labs. The number of work or school days missed related
to SCIG was assessed.
Most patients required three nursing visits before
becoming independent with SCIG infusions. 11 infections
were reported over 6246 patient days, or 0.0048 infections/
patient/month. 15 days of school or work activities were
missed, or 0.0026 missed days/patient/month. 18% of
patients reported SCIG related side effects. All were minor
andmanaged at home. This represented 0.34% of all infusions
and is signiﬁcantly lower than the reported 3% side effect
rate of home IVIG.
The average cost per patient for the initial SCIG
training was $309. The subsequent estimated average cost
per patient for drug and supplies was $806 per month
with a mean dose of 2.4 grams/week. The distance from
the home to the outpatient infusion center ranged
between 3 and 103 miles for an average travel time of 73
minutes each way, resulting in a travel time savings of 146
minutes per month when comparing home SCIG to
outpatient IVIG.
Additional clinical assessment included quality of life
interviews that queried the impact of outpatient IVIG vs SCIG
at home on patient-reported issues (compliance, time, side
effects, cost, health and preference). Results will be reported
in detail. Home SCIG enables incorporation of treatment into
life, rather than working life into treatment for select clini-
cally appropriate patients. Nurses are in a unique position to
empower and educate patients and caregivers on individu-
alized options related to immune globulin site of service and
route of administration.494
Communication: Stagtegies to Improve Nurse to Nurse
Handoff and Nurse-Provider Communication
Noel Arring, Doralyn Costello. BMT/Hematology/Oncology,
Mayo Clinic, Phoenix, AZ
Signiﬁcance & Background: The IOM identiﬁed that
communication failures were one of the leading causes of
care breakdown. Communication failures had been identi-
ﬁed in our facility speciﬁcally between nurse and providers
and at nurse to nurse handoffs.
Purpose: The goal of this project was to improve commu-
nication at time of patient hand-offs and to increase
communication between clinical nurses and providers to
decrease errors that reach our patients.
Intervention: This project included an institutional
endeavor which implemented nurse to nurse bedside report.
At the unit level we also implemented structured verbal and
written report and nurse led multi-disciplinary rounds. Our
written report tool is utilized to guide both the nurse to
nurse handoff and our nurse led rounds.
Evaluation: We our now 100% compliant with our bedside
report metrics . We have been able to identify medication
errors through bedside report. Our structured report helped
to maintain our incremental time while being able to convey
our complex patients concisely and quickly. Nurse led rounds
has empowered nurses to be advocates and opened up the
communication between disciplines.
Discussion: our stategies to increase communication has
been successfully incorporated into our units culture. It
took nursing leadership, transparency and linking these
changes to our organizations primary value to gain full
adoption.495
Fall Reduction: Strategies in Action
Noel Arring, Doralyn Costello. BMT/Hematology/Oncology,
Mayo Clinic, Phoenix, AZ
Signiﬁcance & Background: During the last two years our
unit has been trying to address our falls rate. At the start of
this project our unit had the highest rate of falls in our
facility.
Purpose: The goal of this project was to decrease our units
falls.
Intervention: Through an EBP practice project interventions
were identiﬁed. These interventions included staff educa-
tion, patient education, and accountability tools. Staff
education was created based off our already existing falls
policy with an emphasis on the use of bed alarms. Staff
education was disseminated at multiple time points and via
a TeamDays approach andwalking rounds. Patient education
was utilized and incorporated in our pre-hospital education
and at time of admission. Accountability tools were devel-
oped and consistently completed.
Evaluation:We have been able to decrease our fall rate from
our units highest rate of 6.6 to 2.3 per 1,000 patient days.
Accountability was key to our success.
Discussion: Falls initiatives are an on-going process. Many
lessons were learned during our project including how to
maintain staff awareness through transparency and story
telling.
